Local therapy of corneal allograft rejection with cyclosporine

Am J Ophthalmol. 1995 Feb;119(2):189-94. doi: 10.1016/s0002-9394(14)73872-3.


Purpose: We evaluated the therapeutic effect of 0.5% topical cyclosporine on human corneal allograft rejection.

Methods: Sixteen patients (16 eyes) with corneal allograft rejection, refractory to the conventional treatments, were recruited and treated with 0.5% cyclosporine eyedrops in this study.

Results: Of 16 eyes with corneal graft rejection after penetrating keratoplasty treated with 0.5% cyclosporine eyedrops, nine eyes were completely cured, six eyes improved markedly, and treatment was ineffective in one eye. A follow-up of 12 to 24 months (three eyes for 12 months, five eyes for 18 months, and eight eyes for 24 months) disclosed that rejection recurred in three of the nine cured eyes--two eyes after suspension of cyclosporine and one eye after removal of the sutures. The recurrence of rejection resolved by resumption of the cyclosporine eyedrops.

Conclusions: This study demonstrated that treatment of corneal graft rejection with 0.5% topical cyclosporine yielded good results in eyes with satisfactory preoperative corneal transplantation beds and beneficial effects in eyes with poor preoperative corneal transplantation beds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adolescent
  • Adult
  • Child
  • Cornea / drug effects
  • Cornea / pathology
  • Cyclosporine / administration & dosage
  • Cyclosporine / therapeutic use*
  • Female
  • Follow-Up Studies
  • Graft Rejection / drug therapy*
  • Graft Rejection / pathology
  • Graft Rejection / prevention & control
  • Humans
  • Keratoplasty, Penetrating*
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Prognosis
  • Recurrence
  • Transplantation, Homologous


  • Ophthalmic Solutions
  • Cyclosporine